Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone for Electrolyte Supplementation in Preterm Infants with BPD
NCT01721655Phase 3Unknown
- Sponsor
- West Virginia University Health System
- Start
- Oct 2012
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchopulmonary dysplasia (BPD) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Dose of potassium chloride at Day 28. Status: unknown.
02
Drugs
spironolactone
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT01721655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01721655.